


**SCARD Pool report for 01-01-2008 to 31-12-2008**

|                     |                             |        |         |
|---------------------|-----------------------------|--------|---------|
| <b>Participants</b> | Doctors                     | 194    |         |
|                     | Patients                    | 23,046 |         |
| <b>Specimens</b>    | New lesions                 | 39,451 | 85.58%  |
|                     | Previously biopsied lesions | 6,647  | 14.42%  |
|                     | Total lesions               | 46,098 | 100.00% |

**Breakdown of new versus previously biopsied specimens**


|  |        |
|--|--------|
| Percentage of new lesions tested which were malignant          | 57.23% |
| Percentage of Definitively excised lesions that were malignant | 72.63% |
| Lesions tested to find one melanoma (NNT)                      | 8.49   |
| Percentage of lesions tested for NMSC which were NMSC          | 69.35% |
| Ratio of New BCCs : New Melanomas                              | 14:1   |

**Accuracy**
**Diagnostic sensitivity**

|           |                  |
|-----------|------------------|
| Melanomas | 68.72% of 892    |
| All NMSC  | 93.60% of 21,012 |
| BCCs      | 88.72% of 12,140 |
| SCCs      | 78.56% of 8,810  |

**Positive predictive value**

|           |                  |
|-----------|------------------|
| Melanomas | 37.13% of 1,651  |
| All NMSC  | 78.55% of 25,039 |
| BCCs      | 43.02% of 25,039 |
| SCCs      | 62.23% of 11,121 |


**Adequacy**
**Percentage of definitively managed malignant cases where surgical margins were adequate**

|                           |                 |
|---------------------------|-----------------|
| BCC                       | 92.16% of 8,237 |
| IEC/Bowens disease        | 88.84% of 1,532 |
| SCC                       | 93.65% of 3,119 |
| Keratoacanthoma           | 96.24% of 692   |
| Melanoma - in situ        | 84.72% of 530   |
| Melanoma - invasive       | 80.72% of 249   |
| Melanoma - invasive > 1mm | 83.33% of 18    |
| Other malignant           | 79.41% of 34    |

## Lesion Breakdown

### Histological Diagnosis

|                             |        |        |
|-----------------------------|--------|--------|
| BCC (unspecified type)      | 11,647 | 29.47% |
| BCC - Superficial           | 121    | 0.31%  |
| BCC - Nodular/Solid         | 255    | 0.65%  |
| BCC - Aggressive            | 117    | 0.30%  |
| IEC/Bowens disease          | 3,889  | 9.84%  |
| SCC                         | 3,987  | 10.09% |
| Keratoacanthoma             | 934    | 2.36%  |
| Pinkus Fibroepithelioma     | 0      | 0%     |
| Merkel cell tumour          | 1      | 0.00%  |
| Other malignant             | 60     | 0.15%  |
| NMSC Metastasis             | 1      | 0.00%  |
| Melanoma - in situ          | 562    | 1.42%  |
| Melanoma - invasive         | 280    | 0.71%  |
| Melanoma - invasive > 1mm   | 41     | 0.10%  |
| Melanoma - metastasis       | 9      | 0.02%  |
| MELTUMP                     | 0      | 0%     |
| Naevus - other              | 2,145  | 5.43%  |
| Naevus - dysplastic/Clark   | 2,135  | 5.40%  |
| Naevus - blue               | 171    | 0.43%  |
| Naevus - Spitz/Reed         | 47     | 0.12%  |
| Naevus - Compound           | 0      | 0%     |
| Solar keratosis             | 4,149  | 10.50% |
| Solar lentigo               | 600    | 1.52%  |
| Seborrhoeic keratosis       | 2,328  | 5.89%  |
| Lentigo Simplex             | 0      | 0%     |
| Lichenoid keratosis (LPLK)  | 759    | 1.92%  |
| Dermatofibroma              | 271    | 0.69%  |
| Sebaceous gland hyperplasia | 116    | 0.29%  |
| Benign cyst                 | 702    | 1.78%  |
| Other benign                | 2,944  | 7.45%  |
| Histology Pending           | 69     | 0.17%  |



**Procedures**
**Definitive Surgical Management used to exclude melanoma**

|                       |       |        |
|-----------------------|-------|--------|
| Ellipse               | 2,019 | 72.44% |
| Flap                  | 42    | 1.51%  |
| Graft - SSG           | 4     | 0.14%  |
| Graft - FTSG          | 0     | 0%     |
| No Closure            | 18    | 0.65%  |
| Shave/Saucerisation   | 513   | 18.41% |
| Curettage & Cautery   | 117   | 4.20%  |
| Liquid N2 freeze/thaw | 2     | 0.07%  |
| PDT                   | 0     | 0%     |
| Imiquimod             | 0     | 0%     |
| 5 FU cream            | 0     | 0%     |
| GP referral           | 0     | 0%     |
| Specialist referral   | 13    | 0.47%  |
| Other                 | 59    | 2.12%  |

**Biopsy used to exclude melanoma**

|                 |       |        |
|-----------------|-------|--------|
| Punch - sample  | 737   | 13.72% |
| Shave - sample  | 694   | 12.92% |
| Incisional      | 97    | 1.81%  |
| Punch - removal | 740   | 13.78% |
| Shave - removal | 863   | 16.07% |
| Excisional      | 2,209 | 41.14% |
| Curettage       | 17    | 0.32%  |
| Other           | 12    | 0.22%  |

**Breakdown of definitive management procedures for malignant conditions**

|                       |        |        |
|-----------------------|--------|--------|
| Ellipse               | 12,489 | 65.14% |
| Flap                  | 1,630  | 8.50%  |
| Graft - SSG           | 81     | 0.42%  |
| Graft - FTSG          | 308    | 1.61%  |
| No Closure            | 78     | 0.41%  |
| Shave/Saucerisation   | 281    | 1.47%  |
| Curettage & Cautery   | 2,871  | 14.97% |
| Liquid N2 freeze/thaw | 200    | 1.04%  |
| PDT                   | 103    | 0.54%  |
| Imiquimod             | 269    | 1.40%  |
| 5 FU cream            | 193    | 1.01%  |
| GP referral           | 1      | 0.01%  |
| Specialist referral   | 496    | 2.59%  |
| Other                 | 172    | 0.90%  |

**Breakdown of definitive management procedures for benign conditions**

|                       |       |        |
|-----------------------|-------|--------|
| Ellipse               | 2,932 | 62.20% |
| Flap                  | 40    | 0.85%  |
| Graft - SSG           | 5     | 0.11%  |
| Graft - FTSG          | 8     | 0.17%  |
| No Closure            | 26    | 0.55%  |
| Shave/Saucerisation   | 811   | 17.20% |
| Liquid N2 freeze/thaw | 223   | 4.73%  |
| 5 FU cream            | 62    | 1.32%  |
| GP referral           | 0     | 0%     |
| Specialist referral   | 21    | 0.45%  |
| Other                 | 102   | 2.16%  |

**Procedures (continued)**
**Percentage of procedures/closures that were complex**

|  |                |
|--|----------------|
| Complex Closures                           | 0.97% of 5,491 |
| Complex Closures (inc Curettage & Cautery) | 0.89% of 5,963 |

**Locations**
**Breakdown of melanomas by location and percentage melanomas of total lesions at that location**

|               |     |                |
|---------------|-----|----------------|
| Nose          | 20  | 0.85% of 2,366 |
| Lip           | 2   | 0.30% of 659   |
| Ear           | 14  | 1.03% of 1,360 |
| Eyelid        | 1   | 0.25% of 396   |
| Other face    | 65  | 1.78% of 3,652 |
| Scalp         | 21  | 1.89% of 1,111 |
| Neck          | 32  | 1.50% of 2,132 |
| Shoulder      | 70  | 3.35% of 2,091 |
| Chest         | 45  | 1.82% of 2,475 |
| Abdomen       | 17  | 2.87% of 593   |
| Genitalia     | 0   | 0% of 64       |
| Back          | 259 | 4.28% of 6,048 |
| Buttock       | 2   | 1.77% of 113   |
| Arm           | 75  | 3.55% of 2,111 |
| Forearm       | 60  | 1.96% of 3,064 |
| Hand Dorsal   | 0   | 0% of 1,493    |
| Hand Palmar   | 0   | 0% of 15       |
| Finger Dorsal | 0   | 0% of 310      |
| Finger Nail   | 0   | 0% of 0        |
| Finger Palmar | 0   | 0% of 1        |
| Thigh         | 56  | 4.13% of 1,356 |
| Leg           | 99  | 2.21% of 4,473 |
| Foot Dorsal   | 1   | 0.32% of 317   |
| Foot Plantar  | 3   | 5.77% of 52    |
| Toe Dorsal    | 0   | 0% of 53       |
| Toe Nail      | 0   | 0% of 0        |
| Toe Plantar   | 0   | 0% of 5        |
| Palm Or Sole  | 0   | 0% of 0        |

